Showing results (101-110 of 128) with videos related to
Sort By:
Pageof 13
Leukemia & Lymphoma|May 19, 2020
Venetoclax is safe and efficacious in relapsed/refractory AMLChezi Ganzel, Ron Ram, Alexander Gural, et al.Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|February 20, 2022
The effect of a third-dose BNT162b2 vaccine on anti-SARS-CoV-2 antibody levels in immunosuppressed patientsEsther Saiag, Ayelet Grupper, Irit Avivi, et al.British Journal of Haematology|May 23, 2024
Gilteritinib with or without venetoclax for relapsed/refractory FLT3-mutated acute myeloid leukaemiaEitan Kugler, Inbar Cohen, Irina Amitai, et al.European Journal of Haematology|March 25, 2023
Response rates of extra-nodal diffuse large B cell lymphoma to anti-CD19-CAR T cells: A real word retrospective multicenter studyOfrat Beyar Katz, Chava Perry, Sigal Grisariu-Greenzaid, et al.Transplantation and Cellular Therapy|July 2, 2021
Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients after Allogeneic HCT or CD19-based CART therapy-A Single-Center Prospective Cohort StudyRon Ram, David Hagin, Nino Kikozashvilli, et al.Journal for Immunotherapy of Cancer|February 9, 2025
Real-world outcomes with tisagenlecleucel in aggressive B-cell lymphoma: subgroup analyses from the CIBMTR registryDaniel J Landsburg, Matthew J Frigault, Michael Heim, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 30, 2016
Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating AgentsValeria Santini, Antonio Almeida, Aristoteles Giagounidis, et al.Cancer Research|October 10, 2025
Distinct Cellular and Molecular Patterns in Pretreatment Peripheral Blood Are Associated with CAR T-cell Outcomes in Diffuse Large B-cell LymphomaAnna Gurevich-Shapiro, Pascale Zwicky, Eitan Winter, et al.Leukemia & Lymphoma|September 28, 2020
Outcome of relapsed/refractory diffuse large B-cell lymphoma patients treated with polatuzumab vedotin-based therapy: real-life experienceYafit Segman, Elena Ribakovsky, Abraham Avigdor, et al.Bone Marrow Transplantation|June 19, 2026
The impact of IPI risk factors on CAR T-cell therapy or allogeneic stem cell transplantation for treatment of relapsed or refractory large B-cell lymphoma (LBCL)Anna Ossami Saidy, Ariane Boumendil, Peter Dreger, et al.Pageof 13